Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

Nature

Volumn 451, Issue 7176, 2008, Pages 335-339

  Ebert, Benjamin L ^a,b,c   Pretz, Jennifer ^a   Bosco, Jocelyn ^a   Chang, Cindy Y ^a   Tamayo, Pablo ^a   Galili, Naomi ^d   Raza, Azra ^d   Root, David E ^a   Attar, Eyal ^e   Ellis, Steven R ^f   Golub, Todd R ^a,b,g  

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f UNIVERSITY OF LOUISVILLE   (United States)

^g HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN RSP14; RIBOSOME PROTEIN; UNCLASSIFIED DRUG;

CANCER; GENE; IDENTIFICATION METHOD; MUTATION; PHENOTYPE; PROTEIN; RNA; TUMOR;

ARTICLE; CELL DIFFERENTIATION; CHROMOSOME DELETION 5; CONTROLLED STUDY; GENE FUNCTION; GENETIC SCREENING; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RIBOSOME SUBUNIT; RNA INTERFERENCE;

EID: 38349088899     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature06494     Document Type: Article

References (30)

1. Knudson, A. G. Jr. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA 68, 820-823 (1971).
2. Van den Berghe, H. et al. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature 251, 437-438 (1974).
3. Heaney, M. L. & Golde, D. W. Myelodysplasia. N. Engl. J. Med. 340, 1649-1660 (1999).
4. Giagounidis, A. A., Germing, U. & Aul, C. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin. Cancer Res. 12, 5-10 (2006).
5. List, A. et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N. Engl. J. Med. 355, 1456-1465 (2006).
6. - syndrome. Blood 99, 4638-4641 (2002).
7. Raza, A. et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 86, 268-276 (1995).
8. Zender, L. et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125, 1253-1267 (2006).
9. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545-15550 (2005).
10. Ferreira-Cerca, S. et al. Roles of eukaryotic ribosomal proteins in maturation and transport of pre-18S rRNA and ribosome function. Mol. Cell 20, 263-275 (2005).
11. Draptchinskaia, N. et al. The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nature Genet. 21, 169-175 (1999).
12. Gazda, H. T. et al. Ribosomal protein S24 gene is mutated in Diamond-Blackfan anemia. Am. J. Hum. Genet. 79, 1110-1118 (2006).
13. Flygare, J. et al. Human RPS19, the gene mutated in Diamond-Blackfan anemia, encodes a ribosomal protein required for the maturation of 40S ribosomal subunits. Blood 109, 980-986 (2007).
14. Liu, J. M. & Ellis, S. R. Ribosomes and marrow failure: coincidental association or molecular paradigm? Blood 107, 4583-4588 (2006).
15. Quesenberry, P. J. & Colvin, G. A. in Williams Hematology 153 (McGraw-Hill, New York, 2005).
16. Quigley, J. G. et al. Identification of a human heme exporter that is essential for erythropoiesis. Cell 118, 757-766 (2004).
17. Amsterdam, A. et al. Many ribosomal protein genes are cancer genes in zebrafish. PLoS Biol. 2, E139 (2004).
18. Horrigan, S. K. et al. Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31. Blood 95, 2372-2377 (2000).
19. Liu, T. X. et al. Chromosome 5q deletion and epigenetic suppression of the gene encoding α-catenin (CTNNA1) in myeloid cell transformation. Nature Med. 13, 78-83 (2007).
20. Joslin, J. M. et al. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood 110, 719-726 (2007).
21. Fodde, R. & Smits, R. Cancer biology. A matter of dosage. Science 298, 761-763 (2002).
22. Mullighan, C. G. et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446, 758-764 (2007).
23. Ebert, B. L. et al. An RNA interference model of RPS19 deficiency in Diamond-Blackfan anemia recapitulates defective hematopoiesis and rescue by dexamethasone: identification of dexamethasone-responsive genes by microarray. Blood 105, 4620-4626 (2005).
24. Moffat, J. et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124, 1283-1298 (2006).
25. Golub, T. R. et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531-537 (1999).
26. Ebert, B. L. et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med. (in the press).
27. Stegmaier, K. et al. Gene expression-based high-throughput screening (GE-HTS) and application to leukemia differentiation. Nature Genet. 36, 257-263 (2004).
28. Gnatenko, D. V. et al. Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood 101, 2285-2293 (2003).
29. Bolstad, B. M., Irizarry, R. A., Astrand, M. & Speed, T. P. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19, 185-193 (2003).
30. Tang, H. et al. Amino acid-induced translation of TOP mRNAs is fully dependent on phosphatidylinositol 3-kinase-mediated signaling, is partially inhibited by rapamycin, and is independent of S6K1 and rpS6 phosphorylation. Mol. Cell. Biol. 21, 8671-8683 (2001).